8-K: Lantern Pharma Secures $15.53 Million At-The-Market Equity Offering Facility

Lantern Pharma Inc. has entered into an At-The-Market Sales Agreement with ThinkEquity LLC to potentially sell up to $15.53 million of common stock, providing flexible access to capital.

Summary

• Lantern Pharma Inc. (LTRN) entered into an At-The-Market (ATM) Sales Agreement with ThinkEquity LLC on July 3, 2025.
• The agreement allows the company to offer and sell up to $15,530,000 in aggregate offering price of common stock from time to time.
• ThinkEquity LLC will act as the sales agent, selling shares in at-the-market offerings, negotiated transactions, or other permitted methods.
• Lantern Pharma will pay ThinkEquity LLC a commission of 3.0% of the aggregate gross proceeds from the sale of the Placement Shares.
• The company is not obligated to sell any shares under the agreement, retaining discretion over the timing and amount of sales.
• The offering is registered under a Form S-3 registration statement (File No. 333-279718), which was declared effective on June 10, 2024, with a prospectus supplement filed on July 3, 2025.

Sentiment

Score: 7

Explanation: The agreement provides Lantern Pharma with a flexible and efficient mechanism to raise capital, which is generally positive for a growth-oriented biotech company. While it introduces potential dilution, the ability to control the timing and amount of sales mitigates immediate negative impact and provides financial optionality.

Positives

• Provides Lantern Pharma with a flexible and efficient mechanism to raise capital as needed, without the necessity of a traditional underwritten offering.
• Allows the company to access public markets opportunistically based on prevailing market conditions and its capital requirements.
• The company is not obligated to sell shares, retaining control over the timing and pricing of any sales, which offers strategic financial management.

Negatives

• Potential for dilution of existing shareholders if the company sells a significant number of shares under the program.
• The existence of an ATM program can create an overhang on the stock, potentially impacting share price due to the possibility of future share issuances.
• A 3.0% commission to the agent reduces the net proceeds received by the company from sales, increasing the cost of capital compared to direct sales.

Risks

• There is no assurance that the Agent will be successful in selling Placement Shares, meaning the company may not raise the desired capital.
• The company faces potential liability and expenses if it defaults on its obligation to deliver Placement Shares.
• Material adverse changes in the company's financial condition, business, operations, earnings, properties, or prospects could make it impractical or inadvisable to market the Placement Shares.
• Adverse changes in the financial markets, outbreaks of hostilities, or other calamities or crises could disrupt the ability to sell shares.
• Suspension or delisting of the Common Stock from The Nasdaq Stock Market would prevent sales under the agreement.
• Issuance of a stop order by the SEC or other governmental authority could suspend the effectiveness of the registration statement.
• The company is subject to various laws and regulations, including Health Care Laws, Environmental Laws, Anti-Corruption Laws, FCPA, and Money Laundering Laws, with potential for Material Adverse Effect if not in compliance.
• Challenges to the company's Intellectual Property rights could have a Material Adverse Effect on its business.
• Cyber security breaches or compromises of IT Systems and Data could result in material liabilities and operational disruptions.
• Labor disturbances or disputes with employees could reasonably be expected to result in a Material Adverse Effect.

Future Outlook

The ATM Sales Agreement provides Lantern Pharma Inc. with a flexible financing tool to raise capital from time to time, up to a maximum of $15,530,000, to support its operations and strategic initiatives. The company is not obligated to sell any shares, allowing it to manage its capital needs opportunistically based on market conditions.

Management Comments

• Lantern Pharma Inc. entered into an ATM Sales Agreement with ThinkEquity LLC, signed by Panna Sharma, President and Chief Executive Officer, and David Margrave, Chief Financial Officer, indicating management's commitment to securing flexible financing options.

Industry Context

At-the-market (ATM) equity offerings are a common financing strategy for biotechnology and pharmaceutical companies. These companies often require significant capital for research and development, clinical trials, and potential commercialization, and ATM programs provide a flexible and cost-effective way to raise funds incrementally, minimizing the immediate dilutive impact compared to large, single underwritten offerings. This allows companies like Lantern Pharma to access capital as needed to fund their drug development pipelines.

Comparison to Industry Standards

• NA. This document details a financing mechanism rather than operational or financial performance results that could be directly compared to specific industry benchmarks or competitor projects. ATM offerings are a standard tool in the biotech industry for capital raising.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock, which could impact per-share value. However, the capital raised could fund critical operations and R&D, potentially increasing long-term company value.
• Company: Gains significant financial flexibility and access to capital for general corporate purposes, including funding research and development, clinical trials, and working capital needs.
• Creditors: Improved liquidity and financial stability resulting from potential capital raises could be viewed positively, enhancing the company's ability to meet its obligations.

Next Steps

• Lantern Pharma Inc. may, at its discretion, issue and sell common stock under the ATM Sales Agreement based on its capital needs and market conditions.
• The company will file prospectus supplements with the SEC detailing the amount of Placement Shares sold, net proceeds, and agent compensation during relevant periods.
• The company will continue to comply with SEC reporting requirements and Nasdaq listing standards related to the offering.

Key Dates

Recommendation

Keywords

Lantern Pharma, LTRN, ATM Sales Agreement, At-The-Market, Equity Offering, Common Stock, Capital Raise, ThinkEquity LLC, SEC Filing, Form 8-K, Dilution, Nasdaq, Biotechnology, Pharmaceutical, Financing